Recombinant Human C-C Motif Chemokine 13 Protein (CCL13), Active
Beta LifeScience
SKU/CAT #: BLC-05509P
Recombinant Human C-C Motif Chemokine 13 Protein (CCL13), Active
Beta LifeScience
SKU/CAT #: BLC-05509P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human C-C Motif Chemokine 13 Protein (CCL13), Active is produced by our E.coli expression system. This is a protein fragment. |
Purity | Greater than 96% as determined by SDS-PAGE and HPLC. |
Endotoxin | Less than 1.0 EU/μg as determined by LAL method. |
Activity | Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human monocytes is in a concentration of 10-100 ng/ml. |
Uniprotkb | Q99616 |
Target Symbol | CCL13 |
Synonyms | C-C motif chemokine 13; CCL13; CCL13_HUMAN; Chemokine (C C motif) ligand 13; CK beta 10; CK-beta-10; CKb10; MCP-4; MGC17134; Monocyte chemoattractant protein 4; Monocyte chemotactic protein 4; NCC 1; NCC-1; NCC1; New CC chemokine 1; SCYA13; SCYL1; short chain; Small inducible cytokine A13 precursor; Small inducible cytokine subfamily A (Cys Cys) member 13; Small-inducible cytokine A13 |
Species | Homo sapiens (Human) |
Expression System | E.coli |
Tag | Tag-Free |
Complete Sequence | QPDALNVPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWVQ NYMKHLGRKA HTLKT |
Expression Range | 24-98aa |
Protein Length | Partial |
Mol. Weight | 8.6 kDa |
Research Area | Immunology |
Form | Lyophilized powder |
Buffer | Lyophilized from a 0.2 µm filtered PBS, pH 7.4 |
Reconstitution | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
Storage | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
Notes | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
Target Details
Target Function | Chemotactic factor that attracts monocytes, lymphocytes, basophils and eosinophils, but not neutrophils. Signals through CCR2B and CCR3 receptors. Plays a role in the accumulation of leukocytes at both sides of allergic and non-allergic inflammation. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. May play a role in the monocyte attraction in tissues chronically exposed to exogenous pathogens. |
Subcellular Location | Secreted. |
Protein Families | Intercrine beta (chemokine CC) family |
Database References | |
Tissue Specificity | Widely expressed. Found in small intestine, thymus, colon, lung, trachea, stomach and lymph node. Low levels seen in the pulmonary artery smooth muscle cells. |
Gene Functions References
- CCL13 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
- CCL13 levels in serum and synovial fluid may serve as a biomarker for the progression of osteoarthritis. PMID: 25654294
- CCL13 is an antimicrobial protein with bacteriocidal activity against E. coli. PMID: 12949249
- Data suggest that CCL13 binds to several chemokine receptors (CCR1, CCR2, and CCR3), allowing CCL13 to elicit different effects on target cells of immune system. CCL13 is involved in pathology of chronic inflammatory/autoimmune diseases. [REVIEW] PMID: 23846739
- MCP-4 and hsCRP may be the markers linking chronic inflammation in obesity and periodontal disease. PMID: 23375121
- E(2) has adverse effects on the pathogenesis of RA as a result of unregulated cell death, increased TNF-alpha-induced MMP-3 production, and CCL13 overproduction, subsequently resulting in the disease progression of RA. PMID: 22393877
- Findings suggest that the pro-atherogenic effects of CCR2 may not be restricted to interaction with MCP-1, but could also involve activation by MCP-4, being an inflammatory link between platelet and monocyte activation. PMID: 20139115
- Data suggest that the monocyte chemoattractant protein-4 core promoter YY-1 binding motif is functional, and modulates the transcriptional regulation of the MCP-4 gene. PMID: 12805085
- The study was undertaken to understand the relationship between the functional proteomics of receptor-Ck and developmental stages of human atherosclerotic aortic wall. PMID: 14560935
- MCP-4 may be a critical molecule that links obesity and chronic inflammation. PMID: 16855189
- The Th2 cytokine IL-4 preferentially stimulated MCP-4 expression. PMID: 17541284
- interferon-gamma with IL-1beta/TNF-alpha activates the production of CCL13 from chondrocytes in RA joints; secreted CCL13 enhances fibroblast-like synoviocyte proliferation by activating the extracellular signal-regulated MAP kinases cascade PMID: 17824960
- TLR2, 3, 4 and 5 ligands, but not TLR7/8 or 9 ligands, synergized with IL-4 to induce the production of MCP-4 in nasal polyp fibroblasts. PMID: 17851891
- CCL13 and HSPC159 mRNA expressions in PBMC are up-regulated specifically in MCNS patients during the nephrosis phase. PMID: 18219197
- Oncostatin M can strongly up-regulate the expression of CCL13, a chemokine recently identified in the synovial fluid of patients with rheumatoid arthritis. PMID: 19565514